SEK 2.28
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Based in Stockholm, Sweden, ODI Pharma AB (publ) is a pharmaceutical enterprise that commenced operations in 2018. This company specializes in the manufacture and supply of both medicinal cannabis and cosmetic items throughout Europe. Its product line includes cannabidiol-enriched skincare solutions, such as facial creams, masks, and body balms, all sold under the Kandol. brand via its e-commerce site, kandol.net.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA.
Data is available to registered users only